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  Human thrombin activatable fibrinolysis inhibitor (TAFI) 
is a carboxypeptidase zymogen that was first described in 
1995 [1]. It had been previously reported under different 
names such as carboxypeptidase basic (B), unstable (U), and 
arginine (R) [2]. The mature TAFI protein contains 401 
amino acids, and after glycosylation, the molecular weight 
becomes 60 kDa. TAFI in its plasma zymogen form can 
be activated by thrombin, the thrombin-thrombomodulin 
complex, or plasmin. The activated TAFI (TAFIa) decays 
spontaneously into the inactive form of TAFI (TAFIai) 
through a temperature-dependent conformational change. 
  TAFIa plays a role in the inhibition of fibrinolysis by 
cleaving the carboxyl-terminal lysine residues from partially 
degraded fibrin. In the coagulation cascade, the generated 
thrombin can activate TAFI, and the resulting TAFIa inhibits 
fibrinolysis, finally resulting in the formation of more stable 
clots [3]. Therefore, a deficiency of the coagulation factors 
might reduce the TAFIa levels via reduced thrombin gen-
eration, resulting in the formation of an unstable clot. In 
an animal study, TAFI was activated during a thrombotic 
event, and the inhibition of TAFIa activity enhanced the 
efficacy of thrombolytic therapy, thereby confirming its 
role as an inhibitor of fibrinolysis [4-6]. TAFIa also plays 
a role in the modulation of inflammation through down-reg-
ulation of pericellular plasminogen activation and inacti-
vation of the inflammatory peptides bradykinin and anaphy-
latoxins C3a and C5a. In mice with Escherichia coli-induced 
sepsis, TAFI deficiency prevented liver damage via in-
activation of C3a and C5a [7]. 
  The plasma concentration of TAFI appears to be under 
the control of genetic factors and non-genetic factors such 
as sex hormones, cytokines, and lipids [2]. Several diseases, 
including diabetes, kidney transplantation, hypertension, 
nephritic syndrome, insulin resistance, obesity, and in-
flammatory bowel disease, have been shown to be positively 
associated with plasma TAFI levels [2]. Because TAFI is 
expressed in adipocytes, an increased TAFI level can be 
expected in metabolic disturbance. The TAFI levels were 
also elevated in thrombotic diseases. In keeping with the 
role of TAFI as an antifibrinolytic factor, high plasma level 
of TAFI is a risk factor for thrombotic diseases. Meanwhile, 
TAFI levels are reduced in acquired hemostatic dysfunc-
tions, such as post-partum hemorrhage and sepsis accom-
panying disseminated intravascular coagulation [3], because 
the enhanced generation of thrombin or plasmin may result 
in enhanced TAFI activation and consequent consumption 
of the TAFI zymogen. 
  Many different methods for measuring TAFI by using 
ELISA, enzymological methods, or functional methods have 
been described. All the methods have their inherent advan-
tages and disadvantages, and to date, there is no reference 
standard for TAFI. Most studies have used the total antigen 
level of TAFI, but this has yielded ambiguous results, because 
of the existence of different isoforms and various degrees 
of activation. Ceres et al. [8] have reported the use of an 
ELISA that specifically detects TAFI activation. Since sub-
stantial TAFI activation occurs in acquired hemostatic dys-
function, ELISA that measures the extent of TAFI activation 
is potentially useful. 
  In this issue of the Korean Journal of Hematology, Park 
et al. [9] reported high levels of TAFI activation in sepsis 
patients by measuring TAFIa/ai levels using an ELISA that 
they developed “in-house.” In the “in-house” ELISA, potato 
tuber carboxypeptidase inhibitor was used as a capture agent Korean J Hematol 2010;45:215-6.
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that specifically captured the activated and inactivated TAFI 
isoforms and did not capture the intact TAFI zymogen. 
Although only a few septic patients (n=25) were enrolled 
in the study, the activation status of TAFI could clearly 
differentiate septic patients from healthy controls. This re-
sult is in agreement with the results of a recent study [10] 
that reported a significant elevation of TAFI activation in 
meningococcal infection. Since decreases in total TAFI level 
are associated with increases of TAFI activation level, simul-
taneous determination of total TAFI and TAFI activation 
marker is required to interpret the role of TAFI in acquired 
hemostatic dysfunctions including sepsis.  
  Although the principal physiologic role of TAFI is still 
a matter of debate, TAFI is reported to be an important 
protein in the fibrinolytic system. The advent of more accu-
rate assays for measuring plasma TAFI levels may help vali-
date the mechanism underlying TAFI activation in acquired 
hemostatic dysfunction. This information may help eluci-
date the contribution of the TAFI pathway to acquired he-
mostatic dysfunction and will form the basis of potential 
therapeutic strategies to manipulate the TAFI pathway for 
acquired hemostatic dysfunction. 
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